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Aims: The aim of this studywas to evaluate the antioxidant status and oxidative stress biomarkers in the blood of
children and teenagers with Down syndrome.
Mainmethods: The analysis of enzymatic antioxidant defenses, such as the activities of catalase (CAT), superoxide
dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione transferase (GST),
non-enzymatic antioxidants, such as levels of reduced glutathione (GSH), uric acid (UA) and vitamin E, as well
as oxidative damage indicators, such as protein carbonyls (PC) levels and lipoperoxidation (TBARS), of DS indi-
viduals (n = 20) compared to healthy controls (n = 18). Except the vitamin E was measured by HPLC, all
other markers were measured spectrophotometrically.
Key Findings:Antioxidant enzymes analysis showed signiﬁcant increases in the SOD (47.2%), CAT (24.7%) and GR
(49.6%) activities in DS subjects. No signiﬁcant difference in GPx activity was detected while GST activity (61.2%)
was decreased, and both responses may be consequence of the depletion of GSH (24.9%) levels. There were no
signiﬁcant differences in TBARS levels, while PC levels showed decreased (31.7%) levels compared to healthy
controls, whichmay be related to the increase (16.1%) found in serumUA. Levels of vitamin E showed no signif-
icant differences between DS individuals compared to controls.
Signiﬁcance: The results revealed a systemic pro-oxidant status in DS individuals, evidenced by the increased ac-
tivity of some important antioxidant enzymes, together with decreased GSH levels in whole blood and elevated
UA levels in plasma, probably as an antioxidant compensation related to the redox imbalance in DS individuals.© 2013 Elsevier Inc. All rights reserved.Introduction
The incidence of Down syndrome (DS) is approximately 1/1.000 to
1/1.200 of live births (World Health Organization, 2007). DS is caused
by a chromosomal aberration involving total or partial trisomy of chro-
mosome 21 in humans. The presence of an extra copy of chromosome
21 affects several phenotypic and physiological features. Mental retar-
dation associated with DS is accompanied by learning and memory
deﬁcits, a high rate of repetitive behaviors and impairments in adaptive
behavior. In addition, the brain abnormalities observed in DS have been
linked to an inherent oxidative stress, for example, characteristics of
accelerated aging and high incidence of hyperactivity, with accompany-
ing attention deﬁcits (Ribeiro et al., 2003; Shichiri et al., 2011).
In a region of the distal part of chromosome 21 (21q22 band),
which is tripled and known as the critical region of DS, the superoxide
dismutase 1 (SOD1) gene is located (Antonarakis, 1998). SOD1 catalyzesZoologia, CCB, UFSC, Trindade,
: +55 483315156.
.
ghts reserved.the conversion of superoxide anion (O2•−) into hydrogen peroxide
(H2O2), two of the main reactive oxygen species (ROS) continuously
generated mainly in the aerobic cells in the mitochondria (Halliwell
and Gutteridge, 2006). H2O2 in turn is degraded by catalase (CAT)
and glutathione peroxidase (GPx) into water and molecular oxygen.
Hydrogen peroxide produced in excess is a result of increased SOD1
activitywithout the concomitant increase of complementary antioxidant
defense mechanisms, such as CAT and GPx activity (Halliwell and
Gutteridge, 2006). The accumulation of endogenous H2O2, which is
highly diffusible and relatively stable, therefore is able to generate other
deleterious ROS through the Haber–Weiss–Fenton reactions, in this
way damaging important cellular components, oxidizing biomolecules
such as amino acid residues, proteins, lipids and DNA (Halliwell and
Gutteridge, 2006).
The objective of this study is to evaluate the antioxidant status
through oxidative stress biomarkers present in the blood of children
and adolescents with DS compared to healthy controls, taken into con-
sideration the relatively paucity of information in the speciﬁc literature
(Pallardó et al, 2006; Lott et al., 2011; Komatsu et al., 2013), especially
regarding children with this syndrome.
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Study design
Eighteen healthy children (average age of 6.7 ± 3.0 years showing
inﬂammatory markers within normal ranges) without DS (10 males
and 8 females; 3–12 years) were recruited from the Hospital Infantil
Joana de Gusmão of Florianópolis, Santa Catarina, south Brazil, to consti-
tute the control group. The participants with DS exhibited an average
age of 7.7 ± 3.18 years, and most individuals concentrated in the age
group 6–10 years (65%). These patients followed criteria for inclusion
such as age between 3 and 14 yearswithout thepresence of illnesses as-
sociated with systemic diseases, and were not participating in other
studies. Patients takingmedication or food supplementswere excluded.
The twenty subjects with DS were recruited from two local organiza-
tions for children with DS (“Associação Amigos Down” and “Associação
de Pais e Amigos dos Excepcionais—APAE”). The studyprotocolwas ap-
proved by the Ethics Committee of UFSC according to the national and
international guidelines for research involving human subjects (Resolu-
tion No. 1996 of the National Health Council), which regulate experi-
ments involving human subjects (local protocol CEP N. 2112/2011).
All patients received information about the study and their parents
signed the free and informed consent form.
Sample preparation
The samples were obtained from the antecubital vein in chilled
tubes containing EDTA as anticoagulant, or without EDTA to obtain
serum. Immediately after blood collection a blood fraction (200 μl)
was precipitated in trichloroacetic acid (TCA 12%, 1:4 v/v) for reduced
glutathione (GSH) assays. The remaining blood was centrifuged at
1500 g for 10 min to separate the red cells from plasma. For enzymatic
assays, the red cells were diluted in distilled water (1:4) and hemolysis
was carried out by freezing and thaw procedure. After this, plasma,
serum and the acid extracts were stored in liquid nitrogen (−170 °C)
until analysis of the parameters. Enzymatic evaluations were carried
out in hemolysates, while the contents of GSH were obtained in whole
blood acid extracts. Thiobarbituric acid reactive substances (TBARS),
protein carbonyl and vitamin E contents were examined in plasma.
The inﬂammatory parameters were analyzed in plasma (data not
shown).
Antioxidant enzyme assays
Catalase activity was determined by measuring the decrease in a
freshly prepared 10 mM hydrogen peroxide solution at 240 nm (Aebi,
1984). Superoxide dismutase activitywasmeasured at 480 nmaccording
to the method of epinephrine autoxidation (Misra and Fridovich, 1972)
and modiﬁed by Boveris et al. (1983). Glutathione reductase activity
was measured at 340 nm, by measuring the rate of NADPH oxidation
(Calberg and Mannervik, 1985). Glutathione peroxidase was assayed at
340 nm, through the glutathione/NADPH/glutathione reductase system,
by the reduction of terc-butylhydroperoxide (Flohé and Gunzler, 1984).
Glutathione-S-transferase activity was determined at 340 nm using
CDNB (1-chloro-2,4-dinitrobenzene) as substrate and a 0.15 MGSH con-
centration (Habig et al., 1976). All enzymatic activities were expressed in
milliliters of whole blood.
Reduced glutathione (GSH) assay
Reduced glutathione (GSH) wasmeasured at 412 nm (Beutler et al.,
1963), using the reagent DTNB (2-dithionitrobenzoic acid). After being
centrifuged at 3000 g for 5 min, the supernatants from the acid extracts
were added to 0.25 DTNB in 0.1 M sodiumphosphate buffer pH 8.0, and
the formation of the corresponding thiolate anion was immediatelydetermined. Determinations were expressed in micromoles per millili-
ter of whole blood, using ε = 14.1 mmol−1·cm−1.Determination of serum uric acid (UA)
Serum concentration of uric acid was measured spectrophotometri-
cally using Analisa® kits through a colorimetric method, based on the
oxidation of uric acid, uricase producing a red chromophore measured
at 520 nm.Vitamin E assay
Determinationof vitamin E inplasmawas carried out byhigh perfor-
mance liquid chromatography (HPLC) with UV detection at 292 nm
(Nicoletti et al., 2001). An aliquot of 100 μl of plasma was added to
100 μl of ethanol and vortexed for 10 s and added to 100 μl of hexane,
and again vortexed for 45 s. After centrifugation (8000 g) for 5 min,
75 μl of the supernatant (hexane) was transferred to an Eppendorf
and the hexane was evaporated by nitrogen ﬂow. Then 125 μl
diethylether and 375 μl methanol were added and this mixture was
injected in HPLC. Isocratic elution was carried out with methanol
using a ﬂow rate of 1 ml·min−1. Samples were measured in duplicate
and plasma concentrations of α-tocopherol were determined through
a standard curve and expressed as μmol vitamin E ml−1.Lipid peroxidation assessment (TBARS levels)
Lipid peroxidation in plasmawas determined spectrophotometrical-
ly at 535 nm in triplicate by the thiobarbituric acid method (TBARS)
(Bird andDraper, 1984). Brieﬂy, plasmawas precipitatedwith trichloro-
acetic acid (TCA) followed by the incubation with TBA 0.76%, at 100 °C,
for 60 min in a phosphate buffer at pH 7.4 (60 mM Tris–HCl and
0.1 mM DPTA), at high (100 °C) temperature, the samples were then
centrifuged (5 min, 1500 g) and the absorbance of the pink chromo-
phore was measured, using ε = 1.56 × 105 M−1 cm−1. The values
were expressed in nmol TBARS ml−1.Protein carbonyls (PC)
Oxidative damage promoted by protein carbonylation was deter-
mined using 100 μl of plasma, which were added to 600 μl DPNH
(2,4-dinitrophenyl-hydrazine). Ethanol/ethyl acetate (1:1; v:v) was
used to remove hydrazine excess. After this, incubation with guanidine
chloride (600 μl) was performed and the maximum carbonyl absor-
bance in the range of 360–370 nm was recorded (Levine et al., 1990).
The total protein concentration was determined by the method of
Lowry et al. (1951), using albumin as a standard. The concentration of
carbonyl protein was expressed in nmol·mg−1. All measurements
were carried out in triplicate.Chemicals
All the chemicals and solvents usedwere of analytical grade andpur-
chased from Sigma Chemical Co. (St. Louis, MO, USA).Statistical analysis
Data were expressed as means ± SEM. Unpaired Student t test was
used to compare the different groups. The coefﬁcient of Pearson was
used to evaluate correlations among GST and GPx activity and GSH con-
centrations. Minimal values of p b 0.05 were considered statistically
signiﬁcant.
Fig. 1. Enzymatic activity in hemolysates of (A) superoxide dismutase (SOD), (B) catalase (CAT), (C) glutathione peroxidase (GPx), (D) glutathione reductase (GR), and (E) glutathione S-
transferase (GST). Contents of (F) reduced glutathione (GSH) in whole blood extracts, contents of (G) uric acid (UA) in serum, contents of (H) vitamin E (vit E), (I) substances that react
with thiobarbituric acid (TBARS), and (J) protein carbonyls (PC) in plasma, in Down syndrome subjects (n = 20). Asterisks (*) (***)mean statistical differences for p b 0.05and p b 0.001,
compared to controls (n = 18), respectively.
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There was no signiﬁcant difference between the body mass index
(BMI) of patients with DS (17.9 ± 0.76) compared to controls (16.9 ±
0.61). The values of SOD activity in individualswithDS showed increased
activity (47.2%; values around 120 U SOD·ml−1) compared with the
activity of SOD found in healthy individuals (~63 U SOD·ml−1)
(Fig. 1A). Catalase activity also showed a signiﬁcant (24.7%) increase
(~157 μmol·min−1·ml−1) in DS individuals compared to healthy
controls (~118 μmol·min−1·ml−1) (Fig. 1B). GR also showed a sig-
niﬁcantly higher activity (49.6%; ~1 μmol·min−1·ml−1) in DS patients
compared to controls (~0.5 μmol·min−1·ml−1) (Fig. 1D). GPx activity
in DS patients (~57 μmol·min−1·ml−1) showed no signiﬁcant differ-
ence compared to controls (~59 μmol·min−1·ml−1) (Fig. 1C). Contrary
to the behavior of the other enzymes examined, GST activity was signif-
icantly decreased (61.2%; ~43 μmol·min−1·ml−1) compared to subjects
of the control group (~111 μmol·min−1·ml−1) (Fig. 1E). The concen-
trations of TBARS and vitamin E in plasma also showed no signiﬁcant
difference between the groups. On the other hand, GSH and PC concen-
trations were signiﬁcantly decreased (24.9%; ~1.3 mmol·ml−1 and
31.7%; ~0.03 μmol·mg−1, respectively) in DS subjects compared to
controls (~1 mmol·ml−1 and ~0.02 μmol·mg−1, respectively)
(Fig. 1F, H, I, J). The measurement of uric acid levels in the blood of DS
individuals (~4 mg·dl−1) showed a signiﬁcant increase of 16.1% com-
pared to subjects from the control group (~3 mg·dl−1) (Fig. 1G).
Discussion
The results related to the different biomarkers of oxidative stress
obtained in the present study clearly revealed a systemic pro-oxidant
condition in the blood of DS subjects. The main ﬁndings are the
upregulation found in most of the activity of antioxidant enzymes in
hemolysates as well as the GSH depletion found in whole blood togeth-
er with the increased contents detected in serum urate values. Several
studies carried out on other human pathologies have shown that the
augmented activities found in distinct antioxidant enzymes are a phys-
iological response to compensate the persistent oxidative insult, which
is also present in DS subjects (Halliwell and Gutteridge, 2006).
The enhanced (47.2%) SOD1 activity detected in the present study is
expected in DS patients and also in genetically modiﬁed laboratory
animals that mimic the overexpression of this important antioxidant
enzyme, which is located in the region 21q22 of the chromosome 21
(Brooksbank and Balazs, 1984; Epstein et al., 1987).
Nevertheless, the chronic SOD1 overexpression in all cells that char-
acterizes the trisomy 21 subjects and the consequent overgeneration of
endogenous hydrogen peroxide apparently is not adequately compen-
sated by the relatively modest upregulation of catalase. Therefore, this
chronic imbalance between the levels of both important antioxidant
enzymes (SOD/CAT) and their corresponding substrates (O2•−/H2O2),
thereby favoring the generation of themost deleterious hydroxyl radical
(HO•), is apparently the basis for DS disturbances (Ani et al., 2000;
Vasconcelos et al., 2007), such as neurological and hematological abnor-
malities as well as the accelerated aging process (Aguilar-da-Silva et al.,
2003).
Catalase also showed enhanced activity (24.7%) in DS subjects com-
pared to healthy controls. This CAT upregulation is expected in DS
subjects (Pastor et al., 1998), considering that beside the general inter-
vention of glutathione peroxidase on hydroperoxide detoxiﬁcation, cat-
alase is speciﬁcally able to decompose normal levels of hydrogen
peroxide generation into water and molecular oxygen (Halliwell and
Gutteridge, 2006). However, as mentioned before, such increased activ-
ity seems not to be sufﬁcient to avoid the excess of H2O2 generated by
the overexpression of SOD1 in all cells of trisomy 21 subjects, in this
way contributing to a persistent oxidative stress found in DS subjects.
The cellular response involving GPx activity in the erythrocytes of DS
subjects is controversial (Kedziora and Bartosz, 1988). As found in thepresent work, other related studies also reported no alterations in
this important antioxidant enzyme compared to healthy individuals
(Brooksbank and Balazs, 1983; Vertongen et al., 1984). However,
similar studies revealed enhanced GPx activity, both in humans and
also in laboratory animals (Ceballos et al., 1988; Pastor et al., 1998). To
detoxify hydroperoxides, GPx needs the participation of GSH as a co-
factor leading to the formation of its oxidized form (GSSG), which is
very toxic to cells (Chance et al., 1979). The erythrocytic GPx is the
main enzyme in H2O2 detoxiﬁcation in physiological conditions, while
CAT upregulation occurs when higher levels of this ROS are generated,
as found in all cells of DS subjects (Halliwell and Gutteridge, 2006).
GSH depletion is usually reported in DS subjects (Muchová et al.,
2001; Pastore et al., 2003; Hamed et al., 2011), and it was also detected
in the present study. Such depletionmay also contribute to the relative-
ly low GPx activity, which is a limiting factor to its function (Halliwell
and Gutteridge, 2006). Under oxidative stress the ratio between the
reduced and oxidized form of glutathione (GSH:GSSG) is critical for
the loss of mitochondrial function and cellular viability (Meister and
Anderson, 1983; Schulz et al., 2000). Beside its crucial role as a general
antioxidant including HO• detoxiﬁcation, the other main role of the
GSH cycle is to support GPx and GST activities constantly supplying
and maintaining a high concentration (approximately in the range of
1–10 mM) pool of this important tripeptide, apparently in all aerobic
cells (Wilhelm Filho et al., 2000). Furthermore, GSH also participate
in vitamins E and C regeneration, amino-acid transport, immunolog-
ical functions, cellular signaling, among other important functions
(Halliwell and Gutteridge, 2006), which are jeopardized in DS sub-
jects, thereby contributing to the manifestation of this syndrome.
The results obtained in the present study showed enhanced activity
of GR in DS subjects in accordance with a previous related work (Pastor
et al., 1998). GR is a ﬂavoprotein that allows the continuous conversion
of GSSG to GSH, through the oxidation of NADPH to NADP (Meister and
Anderson, 1983). The GR upregulation found in the blood of DS subjects
probably reﬂects the necessity to counteract the oxidative stress present
in their blood, trying to restore the high tissue concentrations (~99%)
usually reported for normal cell metabolism in all aerobic organisms
(Wilhelm Filho et al., 2000).
Similar to the relatively lowGPx activity detected in the present study,
the decreased activity found in erythrocytic GST fromDS subjects may be
attributable to the GSH depletion. Weak negative correlations measured
through the coefﬁcients of Pearson were found between GST activity
(−0.30) and GPx activity (−0.15) GSH concentrations, probably indicat-
ing the use of GSHby both enzymes. The super-family of distinct isoforms
of glutathione S-transferase, beyond their role in xenobiotic detoxiﬁca-
tion, also helps in the detoxiﬁcation of endogenous hydroperoxides
continuously generated through cellular lipoperoxidation processes
(Danielson and Mannervik, 1985; Hayes and Mclellan, 1999). In this re-
gard, the relatively low GSH levels available for GST and GPx activities,
which are probably limiting their responses to the persistent oxidative
stress present in DS subjects, may be responsible for exacerbating such
oxidative insult.
As found in other studies (Meguid et al., 2010; Campos et al., 2011),
no alterations were found regarding lipid damage by ROS (TBARS
levels), as well as protein damage (PC levels), which were decreased
in DS subjects compared to controls. However, other studies revealed
increased damage to proteins, lipids and DNA (Brooksbank and Balazs,
1984; Ani et al., 2000), including high in vitro lipid oxidation in the
brain of fetuses (Le Pecheur et al., 2005), despite the fact that DS
children possess higher levels ofmonounsaturated fatty acids compared
to healthy children (Santos, 2006), an aspect that may predispose the
latter children to potentially high oxidation processes. In the only
other study that reported protein damage associated to DS, Campos
et al. (2010) found higher oxidation levels in diTyr (dityrosine) in DS
children when compared to their non-DS brothers.
The relatively high levels of urate, a well known and powerful anti-
oxidant (Nagiová et al., 2000; Campos et al., 2011) found in the serum
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2006; Campos et al., 2010, 2011), may reﬂect an antioxidant compensa-
tion for the persistent oxidative insult promoted by the disease. Urate is
able to reduce the peroxil radical (ROO•) to hydroperoxide (ROOH),
blocking its transformation to low-molecular aldehydes, including
the toxic and major product of lipoperoxidation, malondyhaldehyde
(MDA) (Halliwell and Gutteridge, 2006). As a consequence, lower
levels of MDA/TBARS are expected in DS subjects (Ames et al.,
1981; Simão et al., 2008), as found in the present work and in other
related studies.
Vitamin E levels did not show any difference between both studied
groups, a result in accordance with other related study (Meguid et al.,
2010). However, inDSpatientswhowere also diagnosedwith Alzheimer
disease, plasma contents of vitamin E were lower compared with DS
patients not showing this neurodegenerative disease (Jackson et al.,
2008).Lockrow et al. (2009) reported that vitamin E supplemented
Ts65Dn rats, a murine model of DS, oxidative stress was attenuated
by this antioxidant intervention, strongly suggesting that an early
antioxidant treatment could be useful (Zana et al., 2007). This
liposoluble chain-breaker protects membranes of cells and organ-
elles and also avoiding LDL oxidation (Halliwell and Gutteridge,
2006), and requires GSH, ascorbate and coenzime Q10 (ubiquinol)
as synergic co-antioxidants (Halliwell and Gutteridge, 2006). Accord-
ingly, some previous reports showed that the early supplementation
of micronutrients such as vitamins E, C and B6, folic acid, zinc, selenium,
α-lipoic acid and L-cysteine, is able to prevent or delay cognitive
retardment in DS patients (Ani et al., 2000; Thiel and Fowkes, 2005).
However, no cognitive improvement in DS patients after an antioxidant
intervention was found (Lott 2011; Lott, 2012). On the other hand,
preliminary results from our laboratory after six months of vitamins E
and C intervention indicate a signiﬁcant attenuation of the systemic ox-
idative stress in DS patients.
Conclusions
The present study showed that the presence of trisomy 21 in chil-
dren and adolescents results in signiﬁcant biochemical changes that
contribute to a systemic and exacerbated oxidative stress in the blood
of DS patients, in a way similar to that already demonstrated by our
group in other chronic diseases where oxidative stress is highlighted
(Maçao et al. 2007; Farias et al. 2012).
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